Market Overview:
The global major depressive disorder market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of depression, rising awareness about mental health disorders, and technological advancements in the field of antidepressants. Based on type, the global major depressive disorder market is segmented into drugs therapy, biological therapy, meditation, physiotherapy, and others. The drugs therapy segment is expected to account for the largest share of this market in 2018. This segment is further divided into SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants), MAOIs (monoamine oxidase inhibitors), and others. The SSRI segment accounted for the largest share of this subsegment in 2017 owing to its high efficacy and safety profile as compared to other drug classes used for treating depression. Based on application, the global major depressive disorder market is divided into under 25 years old, 25-45 years old,, and above 45 years old segments. The under 25 years old segment accounted for the largest share of this market in 2017 owing to increased awareness about mental health disorders among young people coupled with growing incidence rates of depression among them.
Product Definition:
Major Depressive Disorder is a mental disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life. It is the most common type of depressive disorder. Despite being highly prevalent, major depressive disorder remains underdiagnosed and undertreated.
Drugs Therapy:
Drug therapy is the most common treatment for major depressive disorder. It works by changing the chemical balance in the brain and is used as a first line of treatment. The drug therapy market for major depressive disorder has grown significantly over recent years owing to increased awareness, demand and availability of drugs, their effectiveness and safety profile among patients & general public.
Biological Therapy:
Biological therapy is a medical practice that makes use of biological substances and/or devices for the treatment of diseases. Biological therapies include interleukin (IL) inhibitors, monoclonal antibodies, immuno-modulating drugs, and other biologic agents used in the treatment of various diseases such as cancer, rheumatoid arthritis etc. The biological therapy market is segmented on the basis of type and disease.
Application Insights:
Major depressive disorder is a common illness and the World Health Organization (WHO) estimates that it affects around 40 million people across the globe. It also states that depression is the second most widespread disease after diabetes, affecting nearly as many people as asthma and arthritis combined. The WHO further states that major depressive disorder occurs approximately equally among women and men, children, and older adults; however there are some indications which point out more prevalent cases in middle-aged individuals.
The application segment of major depressive disorder includes under 25 years old patients, those aged between 25 to 45 years old, above 45 years old patients along with other applications such as physiotherapy for rehabilitation of physical injuries or pain management for instance neck & back ache. Middle-aged group suffering from MDD accounts for a larger share in various regions due to increased prevalence coupled with awareness regarding treatment facilities amongst this age group which has resulted in higher treatment rates compared to other age groups globally too.
Regional Analysis:
North America dominated the global major depressive disorder market in 2017. The presence of a large number of industry players, favorable government initiatives, and increasing awareness about mental health are some factors responsible for its largest share. In addition, the high adoption rate of new treatment options is expected to drive growth during the forecast period. Asia Pacific is estimated to be fastest-growing region over the forecast period owing to growing healthcare spending by governments and private organizations as well as rising patient awareness levels about available treatments for MDD.
Growth Factors:
- Increasing awareness about Major Depressive Disorder and its symptoms will help to drive the growth of the market.
- Rising incidence of depression due to various reasons such as stress, lifestyle changes, etc., will fuel the demand for Major Depressive Disorder treatments.
- The increasing number of research studies on Major Depressive Disorder is likely to result in new and better treatment options being developed in the near future.
- Growing number of people suffering from mental health disorders will create a larger pool of potential patients for Major Depressive Disorder treatments.
- Availability of government initiatives and funds for research on mental health disorders will provide impetus to the growth of this market
Scope Of The Report
Report Attributes
Report Details
Report Title
Major Depressive Disorder Market Research Report
By Type
Drugs Therapy, Biological Therapy, Meditation, Physiothersapy, Others
By Application
Under 25 Years Old, 25-45 Years Old, Above 45 Years Old
By Companies
Pfizer, Eli Lilly, H. Lundbeck, Otsuka Pharmaceutical, AstraZeneca, Alkermes, Takeda Pharmaceutical, Naurex, Euthymics Bioscience, E-therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Major Depressive Disorder Market Report Segments:
The global Major Depressive Disorder market is segmented on the basis of:
Types
Drugs Therapy, Biological Therapy, Meditation, Physiothersapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Under 25 Years Old, 25-45 Years Old, Above 45 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Eli Lilly
- H. Lundbeck
- Otsuka Pharmaceutical
- AstraZeneca
- Alkermes
- Takeda Pharmaceutical
- Naurex
- Euthymics Bioscience
- E-therapeutics
Highlights of The Major Depressive Disorder Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs Therapy
- Biological Therapy
- Meditation
- Physiothersapy
- Others
- By Application:
- Under 25 Years Old
- 25-45 Years Old
- Above 45 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Major Depressive Disorder Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Major depressive disorder is a mental disorder that causes severe sadness and decreased interest in activities. It can be diagnosed by a doctor after ruling out other possible causes.
Some of the major players in the major depressive disorder market are Pfizer, Eli Lilly, H. Lundbeck, Otsuka Pharmaceutical, AstraZeneca, Alkermes, Takeda Pharmaceutical, Naurex, Euthymics Bioscience, E-therapeutics.
The major depressive disorder market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Major Depressive Disorder Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Major Depressive Disorder Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Major Depressive Disorder Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Major Depressive Disorder Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Major Depressive Disorder Market Size & Forecast, 2020-2028
4.5.1 Major Depressive Disorder Market Size and Y-o-Y Growth
4.5.2 Major Depressive Disorder Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Drugs Therapy
5.2.2 Biological Therapy
5.2.3 Meditation
5.2.4 Physiothersapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Under 25 Years Old
6.2.2 25-45 Years Old
6.2.3 Above 45 Years Old
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Major Depressive Disorder Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Major Depressive Disorder Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Drugs Therapy
9.6.2 Biological Therapy
9.6.3 Meditation
9.6.4 Physiothersapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Under 25 Years Old
9.10.2 25-45 Years Old
9.10.3 Above 45 Years Old
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Drugs Therapy
10.6.2 Biological Therapy
10.6.3 Meditation
10.6.4 Physiothersapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Under 25 Years Old
10.10.2 25-45 Years Old
10.10.3 Above 45 Years Old
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Drugs Therapy
11.6.2 Biological Therapy
11.6.3 Meditation
11.6.4 Physiothersapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Under 25 Years Old
11.10.2 25-45 Years Old
11.10.3 Above 45 Years Old
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Drugs Therapy
12.6.2 Biological Therapy
12.6.3 Meditation
12.6.4 Physiothersapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Under 25 Years Old
12.10.2 25-45 Years Old
12.10.3 Above 45 Years Old
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Drugs Therapy
13.6.2 Biological Therapy
13.6.3 Meditation
13.6.4 Physiothersapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Under 25 Years Old
13.10.2 25-45 Years Old
13.10.3 Above 45 Years Old
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Major Depressive Disorder Market: Competitive Dashboard
14.2 Global Major Depressive Disorder Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Eli Lilly
14.3.3 H. Lundbeck
14.3.4 Otsuka Pharmaceutical
14.3.5 AstraZeneca
14.3.6 Alkermes
14.3.7 Takeda Pharmaceutical
14.3.8 Naurex
14.3.9 Euthymics Bioscience
14.3.10 E-therapeutics
